Cochleovestibulopathy as a Paraneoplastic Syndrome Linked to Breast Cancer: A Case Study of Two Patients and Review of Existing Literature - Takeaways - MDSpire

Cochleovestibulopathy as a Paraneoplastic Syndrome Linked to Breast Cancer: A Case Study of Two Patients and Review of Existing Literature

  • By

  • Liqin Yang

  • Xueqing Liu

  • Wenxia Li

  • Songming Tang

  • Yanan Hu

  • Ting Zhang

  • Xun Li

  • Wei Yue

  • Shujuan Tian

  • December 12, 2025

  • 0 min

Share

  • 1

    Paraneoplastic cochleovestibulopathy (PCVP) is a rare syndrome linked to various malignancies, including breast cancer, characterized by sudden hearing loss and vestibular dysfunction.

  • 2

    The two case studies presented involve Chinese women with PCVP associated with breast cancer, both experiencing sensorineural hearing loss and vertigo.

  • 3

    Despite treatment with steroids and immunotherapy, neither patient showed significant improvement in hearing, highlighting the challenges in managing PCVP.

  • 4

    Diagnostic tests revealed the presence of autoantibodies in one patient, while both cases confirmed breast cancer through imaging and histopathological examination.

  • 5

    The literature review identified 46 additional cases of PCVP, emphasizing the need for increased clinical awareness and understanding of this atypical paraneoplastic syndrome.

Original Source(s)

Cochleovestibulopathy as a Paraneoplastic Syndrome Linked to Breast Cancer: A Case Study of Two Patients and Review of Existing Literature

  • by Liqin Yang, Xueqing Liu, Wenxia Li, Songming Tang, Yanan Hu, Ting Zhang, Xun Li, Wei Yue, Shujuan Tian

  • December 12, 2025

Related Content

Many Insured Patients Still Can’t Afford Hearing Aids, Study Finds

Keck Medicine of USC research reveals which types of health insurance are better at helping patients afford hearing aids — and which aren’t.

  • by

  • May 13, 2025

  • 6 min
Blazing Trails With Research: Paving the Way for Advanced Practice Providers

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.